ANAVIP® [Crotalidae Immune F(ab’)2 (Equine)] is an equine-derived antivenin indicated for the management of adult and pediatric patients with North American rattlesnake envenomation.*

ANAVIP reduced the risk of late coagulopathy when compared with other FDA-approved treatments.1

LATE COAGULOPATHY
Treating North American rattlesnake envonomation has both short-term and long-term considerations¹ˑ²
More info
ANAVIP IS DIFFERENT
A PK profile optimized to match North American rattlesnake venom¹ˑ³ˑ⁴
More info
FULL PRESCRIBING INFORMATION
Download Full Prescribing Information
More info
EFFICACY
ANAVIP reduced the risk of late coagulopathy in a head-to-head clinical trial¹
More info
SAFETY DATA
Learn about the safety data of ANAVIP in a head-to-head clinical trial⁵
More info
DOSING
Standardized dosing eliminates the need for scheduled maintenance dosing after initial control⁵
More info
EDUCATIONAL RESOURCES
Download educational and reference materials
More info
HOW TO ORDER ANAVIP
Contact your wholesaler or call 866-830-7350
More info
CONTACT US
Get personal attention to your questions about ANAVIP
More info
Important Safety Information
INDICATION

ANAVIP® [Crotalidae Immune F(ab’)2 (Equine)] is an equine-derived antivenin indicated for the management of adult and pediatric patients with North American rattlesnake envenomation.

CONTRAINDICATIONS

None.

ADVERSE REACTIONS

The most common adverse reactions observed in more than 2 percent of patients in the clinical trials for ANAVIP were: pruritus, nausea, rash, arthralgia, peripheral edema, erythema, headache, myalgia, pain in extremity, and vomiting.

WARNINGS AND PRECAUTIONS

Hypersensitivity
ANAVIP may cause allergic reactions.

Patients with known allergies to horse protein are particularly at risk for an anaphylactic reaction. If signs or symptoms of anaphylaxis or hypersensitivity reactions (including urticaria, rash, tightness of the chest, wheezing, hypotension) occur, discontinue immediately and institute appropriate treatment.

Monitor patients with follow-up visits for signs and symptoms of delayed allergic reactions or serum sickness (rash, fever, myalgia, arthralgia, pruritus, urticarial rash) and treat appropriately if necessary.

Transmissible Infectious Agents
ANAVIP is made from equine (horse) plasma and may therefore carry a risk of transmitting infectious agents, e.g., viruses.

Reactions to Cresol
Trace amounts of cresol from the manufacturing process are contained in ANAVIP. Localized reactions and generalized myalgias have been reported with the use of cresol as an injectable excipient.

See Full Prescribing Information